Wellington Management Group’s Atea Pharmaceuticals AVIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$307K Sell
57,009
-185,831
-77% -$853K ﹤0.01% 1813
2025
Q4
$867K Sell
242,840
-19,935
-8% -$63.3K ﹤0.01% 1736
2025
Q3
$762K Sell
262,775
-96,676
-27% -$330K ﹤0.01% 1826
2025
Q2
$1.29M Buy
359,451
+54,921
+18% +$164K ﹤0.01% 1677
2025
Q1
$911K Buy
304,530
+86,021
+39% +$268K ﹤0.01% 1722
2024
Q4
$732K Sell
218,509
-3,053
-1% -$10.1K ﹤0.01% 1779
2024
Q3
$742K Sell
221,562
-33,604
-13% -$122K ﹤0.01% 1763
2024
Q2
$845K Sell
255,166
-94,838
-27% -$354K ﹤0.01% 1710
2024
Q1
$1.41M Buy
+350,004
New +$1.37M ﹤0.01% 1603
2023
Q2
Sell
-286,233
Closed -$959K 1816
2023
Q1
$959K Sell
286,233
-11,507
-4% -$46.7K ﹤0.01% 1669
2022
Q4
$1.43M Buy
297,740
+69,775
+31% +$353K ﹤0.01% 1574
2022
Q3
$1.3M Buy
227,965
+139,754
+158% +$1.07M ﹤0.01% 1609
2022
Q2
$626K Sell
88,211
-130
-0.1% -$887 ﹤0.01% 1771
2022
Q1
$637K Buy
88,341
+17,235
+24% +$117K ﹤0.01% 1830
2021
Q4
$635K Buy
71,106
+50,716
+249% +$790K ﹤0.01% 1896
2021
Q3
$715K Sell
20,390
-468,955
-96% -$13M ﹤0.01% 1845
2021
Q2
$10.5M Buy
489,345
+446,979
+1,055% +$13.4M ﹤0.01% 1256
2021
Q1
$2.62M Sell
42,366
-349
-0.8% -$23.6K ﹤0.01% 1570
2020
Q4
$1.78M Buy
+42,715
New +$1.38M ﹤0.01% 1509

Other funds holding AVIR

Wellington Management Group's AVIR Position: Q1 2026 in Review

Wellington Management Group reduced its Atea Pharmaceuticals (AVIR) stake by 77% in Q1 2026, selling an estimated $853K and leaving 57,009 shares worth $307K. The position accounts for ﹤0.01% of the portfolio, ranked #1813.

Wellington Management Group first reported a position in AVIR in Q4 2020 and has held it in 19 quarters since. The position peaked at $10.5M in Q2 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • Wellington Management Group held 57,009 shares of Atea Pharmaceuticals worth $307K as of Q1 2026.
  • Wellington Management Group sold 185,831 Atea Pharmaceuticals shares in Q1 2026, an estimated $853K.
  • Atea Pharmaceuticals made up ﹤0.01% of Wellington Management Group's portfolio in Q1 2026, its #1813 holding.
  • Wellington Management Group first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 19 quarters since.
  • Wellington Management Group's Atea Pharmaceuticals position peaked at $10.5M in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.